Table 3 Sensitivities and specificities based on fixed PC-594 positivity rates in low-risk subjects
From: Metabolic system alterations in pancreatic cancer patient serum: potential for early detection
% Positivity < age 50 (specificity, 95% CI) | USA PC % Sensitivity (95% CI) | % Specificity* (95% CI) | |||
|---|---|---|---|---|---|
USA Control 1 by age | |||||
50-59 | 60-69 | 70-80 | USA control 2 | ||
0.5 (99.5, 98–100) | 7 (0.4-36) | 100 (97–100) | 99 (96–100) | 100 (97–100) | 100 (89–100) |
1.0 (99.0, 97–100) | 21 (6–52) | 99 (95–100) | 95 (91–98) | 97 (93–99) | 100 (89–100) |
2.5 (97.5, 95–99) | 64 (36–86) | 97 (93–99) | 90 (85–94) | 93 (88–96) | 95 (82–99) |
5.0 (95.0, 92–97) | 87 (56–98) | 94 (90–97) | 84 (78–88) | 77 (70–82) | 95 (82–99) |
10.0 (90.0, 87–93) | 100 (73–100) | 90 (85–94) | 74 (68–80) | 67 (60–73) | 83 (67–92) |